Assessment of Non-alcoholic Fatty Lver Disease by Combi-elastography

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044279

Enrollment

Unknown

Registered

2021-03-14

Start date

2021-03-15

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

Gold Standard:Pathological diagnosis

Index test:combi-elastography&#32

and&#32

ATT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with metabolic syndrome who plan to undergo bariatric surgery in the weight loss center of our hospital.

Exclusion criteria

Exclusion criteria: Combined with other causes of liver disease: 1. Patients with alcoholic liver disease. The amount of alcohol consumed > 140 g per week for men and >70g per week for women; 2. Patients with specific diseases that can lead to fatty liver, such as viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease, etc.

Design outcomes

Primary

Measure	Time frame
ATT;combi-elastography;	—

Countries

China

Contacts

Public ContactBo Zhang

Department of Ultrasound, China-Japan Friendship Hospital

779053916@qq.com+86 010-84205417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026